The Cyclophilin Inhibitor Rencofilstat Decreases HCV-induced Hepatocellular Carcinoma Independently of Its Antiviral Activity

Mostrar otras versiones (1)

There is an urgent need for the identification of new drugs that inhibit HCV-induced hepatocellular carcinoma (HCC). Our work demonstrates that cyclophilin inhibitors (CypI) represent such new drugs. We demonstrated that the non-immunosuppressive cyclosporine A (CsA) analog (CsAa) rencofilstat posse...

Descripción completa

Detalles Bibliográficos
Autores principales: Stauffer, Winston, Bobardt, Michael, Ure, Daren, Foster, Robert, Gallay, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462172/
https://www.ncbi.nlm.nih.gov/pubmed/37645728
http://dx.doi.org/10.1101/2023.08.19.553982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462172/
https://www.ncbi.nlm.nih.gov/pubmed/37645728
http://dx.doi.org/10.1101/2023.08.19.553982

Ejemplares similares